|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1985
|
|
gptkbp:ATCCode
|
N06AX12
|
|
gptkbp:brand
|
gptkb:Zyban
gptkb:Aplenzin
gptkb:Forfivo_XL
|
|
gptkbp:CASNumber
|
34911-55-2
|
|
gptkbp:chemicalFormula
|
C13H18ClNO
|
|
gptkbp:contraindication
|
eating disorders
seizure disorder
abrupt discontinuation of alcohol or sedatives
|
|
gptkbp:discoveredBy
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:drugClass
|
norepinephrine reuptake inhibitor
|
|
gptkbp:eliminationHalfLife
|
~21 hours
|
|
gptkbp:form
|
extended-release
immediate-release
sustained-release
|
|
gptkbp:genericName
|
gptkb:bupropion
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Wellbutrin
|
|
gptkbp:interactsWith
|
gptkb:beer
gptkb:levodopa
gptkb:phenytoin
gptkb:MAO_inhibitors
gptkb:ritonavir
gptkb:carbamazepine
cimetidine
antipsychotics
anticonvulsants
antidepressants
nicotine replacement therapy
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
GlaxoSmithKline
|
|
gptkbp:marketedAs
|
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of norepinephrine and dopamine
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notableFor
|
not a selective serotonin reuptake inhibitor (SSRI)
low risk of sexual side effects
not associated with weight gain
stimulating effect
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome_(rare)
hypertension
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
anxiety
headache
insomnia
dry mouth
seizures (rare)
increased sweating
|
|
gptkbp:usedFor
|
gptkb:depression
gptkb:major_depressive_disorder
smoking cessation (as Zyban)
|
|
gptkbp:bfsParent
|
gptkb:bupropion
|
|
gptkbp:bfsLayer
|
6
|